Equity Investment Corp Has $221,000 Stock Position in Cencora, Inc. (NYSE:COR)

Equity Investment Corp lowered its position in shares of Cencora, Inc. (NYSE:COR) by 37.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 981 shares of the company’s stock after selling 592 shares during the quarter. Equity Investment Corp’s holdings in Cencora were worth $221,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of COR. New Millennium Group LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at approximately $26,000. TFO Wealth Partners LLC acquired a new stake in shares of Cencora in the 1st quarter valued at approximately $30,000. LRI Investments LLC acquired a new stake in shares of Cencora in the 1st quarter valued at approximately $31,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at approximately $30,000. Finally, Concord Wealth Partners acquired a new stake in shares of Cencora in the 3rd quarter valued at approximately $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Down 1.3 %

COR stock opened at $240.24 on Monday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The company has a market capitalization of $47.34 billion, a price-to-earnings ratio of 31.99, a PEG ratio of 1.60 and a beta of 0.44. Cencora, Inc. has a fifty-two week low of $194.23 and a fifty-two week high of $251.56. The stock has a fifty day moving average of $232.62 and a 200-day moving average of $231.03.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.92%. Cencora’s dividend payout ratio is 27.16%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on COR shares. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Robert W. Baird increased their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Leerink Partners dropped their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Barclays increased their price target on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Bank of America restated a “neutral” rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $271.20.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This trade represents a 7.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 15.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.